Alpha – Antitrypsin Deficiency – Pipeline Review, H1 Pharmaceutical Research Report 2016

Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Alpha – Antitrypsin Deficiency – Pipeline Review, H1 2016”. The report provides comprehensive information on the therapeutics under development for Alpha- Antitrypsin Deficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Request For Sample Report:

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alpha- Antitrypsin Deficiency and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


– The report provides a snapshot of the global therapeutic landscape of Alpha- Antitrypsin Deficiency
– The report reviews pipeline therapeutics for Alpha- Antitrypsin Deficiency by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Alpha- Antitrypsin Deficiency therapeutics and enlists all their major and minor projects
– The report assesses Alpha- Antitrypsin Deficiency therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Alpha- Antitrypsin Deficiency

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Alpha- Antitrypsin Deficiency
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Full Report With TOC:

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Alpha- Antitrypsin Deficiency Overview 9
Therapeutics Development 10
Pipeline Products for Alpha- Antitrypsin Deficiency – Overview 10
Alpha- Antitrypsin Deficiency – Therapeutics under Development by Companies 11
Alpha- Antitrypsin Deficiency – Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Alpha- Antitrypsin Deficiency – Products under Development by Companies 16
Alpha- Antitrypsin Deficiency – Companies Involved in Therapeutics Development 18
Alnylam Pharmaceuticals, Inc. 18
Annapurna Therapeutics 19
Applied Genetic Technologies Corporation 20
Arrowhead Research Corporation 21
Carolus Therapeutics, Inc. 22
Cevec Pharmaceuticals GmbH 23
Dicerna Pharmaceuticals, Inc. 24
Digna Biotech, S.L. 25
Editas Medicine, Inc. 26
Grifols, S.A. 27
iBio, Inc. 28
Inhibrx 29
International Stem Cell Corporation 30
Ionis Pharmaceuticals, Inc. 31
Kamada Ltd. 32
Polyphor Ltd. 33
ProMetic Life Sciences Inc. 34
rEVO Biologics, Inc. 35
Sangamo BioSciences, Inc. 36
Alpha- Antitrypsin Deficiency – Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
ALN-AAT – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
alpha-1 proteinase inhibitor (human) – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
alpha-1 proteinase inhibitor (human) second generation – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ANN-001 – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ARC-AAT – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
CT-2009 – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
DB-027 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Drugs for Alpha-1 Antitrypsin Deficiency – Drug Profile 55
Product Description 55

Make an Enquiry:

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.


90 State Street,

Albany, NY 12207,

United States

Toll Free : 800-998-4852 (US-Canada)

Email :

Website :

Read Industry News at –

Designed by
Powered by